Form 4: Artiva Biotherapeutics SVP, Research and Development, Heather Raymon, Reports Acquisition of 33,350 Shares
SEC Form 4 Filing
Heather Raymon, SVP of Research and Development at Artiva Biotherapeutics, reports the acquisition of 33,350 shares of common stock on February 26, 2025, as a restricted stock unit award.
Summary
- On February 26, 2025, Heather Raymon, SVP of Research and Development at Artiva Biotherapeutics, acquired 33,350 shares of common stock.
- The acquisition was a result of a restricted stock unit (RSU) award granted under the Issuer's 2024 Equity Incentive Plan.
- Following the transaction, Raymon directly owns 43,350 shares of Artiva Biotherapeutics.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing indicating an executive received stock options, which is neither overtly positive nor negative.
Positives
- The acquisition of shares by a high-ranking officer could be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which is important for maintaining market confidence.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment, as it indicates confidence from a company executive.
Key Dates
| Date | Description |
|---|---|
| 02/26/2025 | Date of the transaction (acquisition of shares) |
| 02/27/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.